Shots:

• Assertio to receive $127.5M including $75M up front in cash and $52.5M as royalties when Gralise net sales reach $75M while Alvogen will get all responsibilities related to the product. The transaction is expected to be close in Jan’2020
• The acquisition allows Assertio to focus on its growth product- Cambia and Zipsor and improve its business development opportunities with the strengthening of its balance sheet. Assertio will provide an update on the financial impact of the sale of Gralise- following the closure of the transaction
• Gralise is a prescription therapy indicated to treat pain after shingles- or postherpetic neuralgia (PHN)

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Behance